Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience

다국어 초록 (Multilingual Abstract)

Ablative treatment of oligometastases has shown survival benefit with certain tumors, al-though these effects still are to be demonstrated in prostate cancer.
Materials and Methods: We analysed the toxicity and clinical control results obtained in patients withbone-only oligometastatic prostate cancer treated with stereotactic ablative radiotherapy (SABR). Ret-rospective study on patients with metachronous oligoprogression and synchronous de novo bone-onlyoligometastatic prostate cancer treated with SABR and androgen deprivation therapy.
Results: Treatment schedules varied according to location and organs at risk, with biologically equiv-alent dose (BED) ≥100 Gy. Fifty-five bone lesions (31 patients) were treated and evaluated for toxicity,local control, progression-free survival (PFS), and overall survival (OS). After a 41-month follow-up,there was minimal acute or chronic toxicity and no G3 toxicity. The local control at 3 and 5 years was100% and 87.1%, respectively. Median PFS and OS were 43 and 98 months, respectively. The best re-sult in PFS was obtained with BED ≥230 Gy, delaying time to the next systemic therapy by 28.5months.
Conclusion: The use of SABR in bone oligometastases of prostate cancer is safe with minimal toxicityand excellent results in local control and PFS, delaying the start of the next systemic therapy.
Keywords: Stereotactic body radiotherapy, Bone oligometastases, Prostate cancer, Next systemictherapy

참고문헌 (Reference)

1 Triggiani L, "Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance" 38 : 72-, 2021

2 Hurmuz P, "Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer : Turkish Society for Radiation Oncology group study(TROD 09-002)" 196 : 1034-1043, 2020

3 Ost P, "Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial" 36 : 446-453, 2018

4 Onal C, "Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients" 48 : 3683-3692, 2021

5 Mazzola R, "Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival : a cohort study" 35 : 121-, 2018

6 Fanetti G, "Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases" 35 : 75-, 2018

7 Muldermans JL, "Stereotactic body radiation therapy for oligometastatic prostate cancer" 95 : 696-702, 2016

8 Palma DA, "Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers : long-term results of the SABR-COMET Phase II Randomized Trial" 38 : 2830-2838, 2020

9 Desai NB, "Stereotactic ablative body radiotherapy(SAbR)for oligometastatic cancer" 90 : 20160500-, 2017

10 Parker CC, "Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial" 392 : 2353-2366, 2018

11 Buglione M, "Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative”intent" 141 : 1-8, 2020

12 Rescigno P, "Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer" 70 : 724-731, 2016

13 van Leeuwen PJ, "Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer" 119 : 209-215, 2017

14 Ost P, "Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence : a multi-institutional analysis" 69 : 9-12, 2016

15 Phillips R, "Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer : the ORIOLE Phase 2 Randomized Clinical Trial" 6 : 650-659, 2020

16 Rogowski P, "Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer" 16 : 125-, 2021

17 Habl G, "Oligometastases from prostate cancer : local treatment with stereotactic body radiotherapy(SBRT)" 17 : 361-, 2017

18 Hellman S, "Oligometastases" 13 : 8-10, 1995

19 Triggiani L, "Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer : a multicenter study" 37 : 2631-2637, 2019

20 Mazzone E, "Location of metastases in contemporary prostate cancer patients affects cancer-specific mortality" 16 : 376-384, 2018

21 Reverberi C, "Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer" 10 : 17471-, 2020

22 Cox BW, "International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery" 83 : e597-605, 2012

23 Scher HI, "Increased survival with enzalutamide in prostate cancer after chemotherapy" 367 : 1187-1197, 2012

24 Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" 71 : 209-249, 2021

25 Beer TM, "Enzalutamide in metastatic prostate cancer before chemotherapy" 371 : 424-433, 2014

26 Boeve LM, "Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial : data from the HORRAD Trial" 75 : 410-418, 2019

27 Santafe-Jimenez A, "Early evaluation of PSA response in metastatic prostate cancer treated with abiraterone" 11 : 251-263, 2021

28 Cornford P, "EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer" 71 : 630-642, 2017

29 Tannock IF, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer" 351 : 1502-1512, 2004

30 Roach M 3rd, "Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer : recommendations of the RTOG-ASTRO Phoenix Consensus Conference" 65 : 965-974, 2006

31 Glicksman RM, "Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer : a prospective phase II trial testing the oligometastasis hypothesis" 80 : 374-382, 2021

32 National Cancer Institute, "Common Terminology Criteria for Adverse Events (CTCAE) version 5" National Cancer Institute

33 Sweeney CJ, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer" 373 : 737-746, 2015

34 Ali A, "Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer : a secondary analysis of a randomized clinical trial" 7 : 555-563, 2021

35 Chi KN, "Apalutamide for metastatic, castration-sensitive prostate cancer" 381 : 13-24, 2019

36 Fizazi K, "Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer" 377 : 352-360, 2017

37 de Bono JS, "Abiraterone and increased survival in metastatic prostate cancer" 364 : 1995-2005, 2011

38 Ryan CJ, "Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COUAA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study" 16 : 152-160, 2015

39 Armstrong AJ, "ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer" 37 : 2974-2986, 2019

40 Zhang B, "A review of stereotactic body radiation therapy in the management of oligometastatic prostate cancer" 40 : 2419-2428, 2020